X

Xilio Therapeutics Inc
NASDAQ:XLO

Watchlist Manager
Xilio Therapeutics Inc
NASDAQ:XLO
Watchlist
Price: 0.665 USD 0.45% Market Closed
Market Cap: 34.9m USD

Wall Street
Price Targets

XLO Price Targets Summary
Xilio Therapeutics Inc

Wall Street analysts forecast XLO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XLO is 2.04 USD with a low forecast of 2.02 USD and a high forecast of 2.1 USD.

Lowest
Price Target
2.02 USD
204% Upside
Average
Price Target
2.04 USD
207% Upside
Highest
Price Target
2.1 USD
216% Upside
Xilio Therapeutics Inc Competitors:
Price Targets
ARMP
Armata Pharmaceuticals Inc
43% Upside
EXAS
Exact Sciences Corp
1% Downside
4593
Healios KK
125% Upside
ZYME
Zymeworks Inc
35% Upside
IMDX
Insight Molecular Diagnostics Inc
23% Upside
LCTX
Lineage Cell Therapeutics Inc
169% Upside
ASMB
Assembly Biosciences Inc
43% Upside
4974
Takara Bio Inc
38% Upside

Revenue
Forecast

Revenue Estimate
Xilio Therapeutics Inc

The compound annual growth rate of Xilio Therapeutics Inc's revenue for the next 4 years is -12%.

N/A
Past Growth
-12%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Xilio Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Xilio Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-47%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XLO's stock price target?
Price Target
2.04 USD

According to Wall Street analysts, the average 1-year price target for XLO is 2.04 USD with a low forecast of 2.02 USD and a high forecast of 2.1 USD.

What is Xilio Therapeutics Inc's Revenue forecast?
Projected CAGR
-12%

The compound annual growth rate of Xilio Therapeutics Inc's revenue for the next 4 years is -12%.

Back to Top